Issue Date: June 14, 2010
Plasma Deal To Join Grifols And Talecris
Grifols, a Spanish producer of plasma protein therapies, has agreed to acquire U.S.-based Talecris for about $3.4 billion. Talecris, a former Bayer business that also develops therapies from blood plasma, has been an acquisition candidate since June 2009, when the Federal Trade Commission blocked Australian plasma protein firm CSL from buying it for $3.1 billion. If this deal is approved, it will result in a company with about $2.8 billion in annual sales.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society